Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates reduced lung function decline with nintedanib in systemic sclerosis–associated interstitial lung disease, suggesting slowed pulmonary progression.
Key Points
- To assess the efficacy and safety of nintedanib compared to placebo in patients with systemic sclerosis-associated interstitial lung disease.
- Randomized, double-blind, placebo-controlled trial (SENSCIS, NCT02597933) comparing nintedanib to placebo in patients with systemic sclerosis-associated interstitial lung disease.
- The primary endpoint evaluated the annual rate of decline in forced vital capacity (FVC), along with systemic disease manifestations and adverse events.
- The annual rate of decline in forced vital capacity was lower in patients receiving nintedanib compared to those receiving placebo.
- No clinical benefit was observed with nintedanib for other manifestations of systemic sclerosis.
- Gastrointestinal adverse events, particularly diarrhea, occurred more frequently with nintedanib than with placebo, consistent with safety profiles in idiopathic pulmonary fibrosis.
Cite This Study
Distler et al. (2019) studied this question.